Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.

BACKGROUND: Fundamental to vaccine development, manufacturing consistency, and product stability is an understanding of the vaccine structure-activity relationship. With the virus-like particle (VLP) approach for recombinant vaccines gaining popularity, there is growing demand for tools that define...

Full description

Bibliographic Details
Main Authors: Anke M Mulder, Bridget Carragher, Victoria Towne, Yuan Meng, Yang Wang, Lance Dieter, Clinton S Potter, Michael W Washabaugh, Robert D Sitrin, Qinjian Zhao
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3320896?pdf=render
_version_ 1818516922915880960
author Anke M Mulder
Bridget Carragher
Victoria Towne
Yuan Meng
Yang Wang
Lance Dieter
Clinton S Potter
Michael W Washabaugh
Robert D Sitrin
Qinjian Zhao
author_facet Anke M Mulder
Bridget Carragher
Victoria Towne
Yuan Meng
Yang Wang
Lance Dieter
Clinton S Potter
Michael W Washabaugh
Robert D Sitrin
Qinjian Zhao
author_sort Anke M Mulder
collection DOAJ
description BACKGROUND: Fundamental to vaccine development, manufacturing consistency, and product stability is an understanding of the vaccine structure-activity relationship. With the virus-like particle (VLP) approach for recombinant vaccines gaining popularity, there is growing demand for tools that define their key characteristics. We assessed a suite of non-intrusive VLP epitope structure and function characterization tools by application to the Hepatitis B surface antigen (rHBsAg) VLP-based vaccine. METHODOLOGY: The epitope-specific immune reactivity of rHBsAg epitopes to a given monoclonal antibody was monitored by surface plasmon resonance (SPR) and quantitatively analyzed on rHBsAg VLPs in-solution or bound to adjuvant with a competitive enzyme-linked immunosorbent assay (ELISA). The structure of recombinant rHBsAg particles was examined by cryo transmission electron microscopy (cryoTEM) and in-solution atomic force microscopy (AFM). PRINCIPAL FINDINGS: SPR and competitive ELISA determined relative antigenicity in solution, in real time, with rapid turn-around, and without the need of dissolving the particulate aluminum based adjuvant. These methods demonstrated the nature of the clinically relevant epitopes of HBsAg as being responsive to heat and/or redox treatment. In-solution AFM and cryoTEM determined vaccine particle size distribution, shape, and morphology. Redox-treated rHBsAg enabled 3D reconstruction from CryoTEM images--confirming the previously proposed octahedral structure and the established lipid-to-protein ratio of HBsAg particles. Results from these non-intrusive biophysical and immunochemical analyses coalesced into a comprehensive understanding of rHBsAg vaccine epitope structure and function that was important for assuring the desired epitope formation, determinants for vaccine potency, and particle stability during vaccine design, development, and manufacturing. SIGNIFICANCE: Together, the methods presented here comprise a novel suite of non-intrusive VLP structural and functional characterization tools for recombinant vaccines. Key VLP structural features were defined and epitope-specific antigenicity was quantified while preserving epitope integrity and particle morphology. These tools should facilitate the development of other VLP-based vaccines.
first_indexed 2024-12-11T00:48:58Z
format Article
id doaj.art-3e93fb88729c42dd9a936a010fd73aaf
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-11T00:48:58Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-3e93fb88729c42dd9a936a010fd73aaf2022-12-22T01:26:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3323510.1371/journal.pone.0033235Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.Anke M MulderBridget CarragherVictoria TowneYuan MengYang WangLance DieterClinton S PotterMichael W WashabaughRobert D SitrinQinjian ZhaoBACKGROUND: Fundamental to vaccine development, manufacturing consistency, and product stability is an understanding of the vaccine structure-activity relationship. With the virus-like particle (VLP) approach for recombinant vaccines gaining popularity, there is growing demand for tools that define their key characteristics. We assessed a suite of non-intrusive VLP epitope structure and function characterization tools by application to the Hepatitis B surface antigen (rHBsAg) VLP-based vaccine. METHODOLOGY: The epitope-specific immune reactivity of rHBsAg epitopes to a given monoclonal antibody was monitored by surface plasmon resonance (SPR) and quantitatively analyzed on rHBsAg VLPs in-solution or bound to adjuvant with a competitive enzyme-linked immunosorbent assay (ELISA). The structure of recombinant rHBsAg particles was examined by cryo transmission electron microscopy (cryoTEM) and in-solution atomic force microscopy (AFM). PRINCIPAL FINDINGS: SPR and competitive ELISA determined relative antigenicity in solution, in real time, with rapid turn-around, and without the need of dissolving the particulate aluminum based adjuvant. These methods demonstrated the nature of the clinically relevant epitopes of HBsAg as being responsive to heat and/or redox treatment. In-solution AFM and cryoTEM determined vaccine particle size distribution, shape, and morphology. Redox-treated rHBsAg enabled 3D reconstruction from CryoTEM images--confirming the previously proposed octahedral structure and the established lipid-to-protein ratio of HBsAg particles. Results from these non-intrusive biophysical and immunochemical analyses coalesced into a comprehensive understanding of rHBsAg vaccine epitope structure and function that was important for assuring the desired epitope formation, determinants for vaccine potency, and particle stability during vaccine design, development, and manufacturing. SIGNIFICANCE: Together, the methods presented here comprise a novel suite of non-intrusive VLP structural and functional characterization tools for recombinant vaccines. Key VLP structural features were defined and epitope-specific antigenicity was quantified while preserving epitope integrity and particle morphology. These tools should facilitate the development of other VLP-based vaccines.http://europepmc.org/articles/PMC3320896?pdf=render
spellingShingle Anke M Mulder
Bridget Carragher
Victoria Towne
Yuan Meng
Yang Wang
Lance Dieter
Clinton S Potter
Michael W Washabaugh
Robert D Sitrin
Qinjian Zhao
Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
PLoS ONE
title Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
title_full Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
title_fullStr Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
title_full_unstemmed Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
title_short Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.
title_sort toolbox for non intrusive structural and functional analysis of recombinant vlp based vaccines a case study with hepatitis b vaccine
url http://europepmc.org/articles/PMC3320896?pdf=render
work_keys_str_mv AT ankemmulder toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT bridgetcarragher toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT victoriatowne toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT yuanmeng toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT yangwang toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT lancedieter toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT clintonspotter toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT michaelwwashabaugh toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT robertdsitrin toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine
AT qinjianzhao toolboxfornonintrusivestructuralandfunctionalanalysisofrecombinantvlpbasedvaccinesacasestudywithhepatitisbvaccine